ES2655209T3 - Métodos para el tratamiento y diagnóstico de enfermedades relacionadas con la densidad mineral ósea - Google Patents

Métodos para el tratamiento y diagnóstico de enfermedades relacionadas con la densidad mineral ósea Download PDF

Info

Publication number
ES2655209T3
ES2655209T3 ES08856341.6T ES08856341T ES2655209T3 ES 2655209 T3 ES2655209 T3 ES 2655209T3 ES 08856341 T ES08856341 T ES 08856341T ES 2655209 T3 ES2655209 T3 ES 2655209T3
Authority
ES
Spain
Prior art keywords
tbxas1
bone
mineral density
acid
bone mineral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08856341.6T
Other languages
English (en)
Spanish (es)
Inventor
Valérie CORMIER-DAIRE
Arnold Munnich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Descartes
Original Assignee
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Université Paris Descartes filed Critical Assistance Publique - Hôpitaux de Paris
Application granted granted Critical
Publication of ES2655209T3 publication Critical patent/ES2655209T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/99—Other intramolecular oxidoreductases (5.3.99)
    • C12Y503/99005—Thromboxane-A synthase (5.3.99.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES08856341.6T 2007-12-07 2008-12-05 Métodos para el tratamiento y diagnóstico de enfermedades relacionadas con la densidad mineral ósea Active ES2655209T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301643 2007-12-07
EP07301643 2007-12-07
PCT/EP2008/066880 WO2009071661A1 (en) 2007-12-07 2008-12-05 Methods for the treatment and diagnosis of bone mineral density related diseases

Publications (1)

Publication Number Publication Date
ES2655209T3 true ES2655209T3 (es) 2018-02-19

Family

ID=39142026

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08856341.6T Active ES2655209T3 (es) 2007-12-07 2008-12-05 Métodos para el tratamiento y diagnóstico de enfermedades relacionadas con la densidad mineral ósea

Country Status (5)

Country Link
US (2) US20100284991A1 (enExample)
EP (1) EP2227560B1 (enExample)
JP (2) JP5512534B2 (enExample)
ES (1) ES2655209T3 (enExample)
WO (1) WO2009071661A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655209T3 (es) 2007-12-07 2018-02-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Métodos para el tratamiento y diagnóstico de enfermedades relacionadas con la densidad mineral ósea
KR102845511B1 (ko) * 2019-02-08 2025-08-12 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN445095A0 (en) * 1995-07-27 1995-08-17 Garvan Institute Of Medical Research Method of predicting bone density
CA2602374A1 (en) * 2005-03-23 2006-09-28 Boehringer Ingelheim International Gmbh Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor
MX2009003761A (es) * 2006-10-04 2009-06-30 Schering Corp Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.
ES2655209T3 (es) 2007-12-07 2018-02-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Métodos para el tratamiento y diagnóstico de enfermedades relacionadas con la densidad mineral ósea

Also Published As

Publication number Publication date
JP2014110788A (ja) 2014-06-19
EP2227560B1 (en) 2017-10-18
EP2227560A1 (en) 2010-09-15
JP5512534B2 (ja) 2014-06-04
WO2009071661A1 (en) 2009-06-11
US20150104437A1 (en) 2015-04-16
JP2011507491A (ja) 2011-03-10
US9834820B2 (en) 2017-12-05
US20100284991A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
EP2882496B1 (en) Treatment and diagnosis of melanoma
US10329354B2 (en) Modulation of efferocytosis pathways for treatment of atherosclerotic disease
Zheng et al. Nogo-B promotes angiogenesis and improves cardiac repair after myocardial infarction via activating Notch1 signaling
JP2012500199A (ja) 血管統合性を促進するマイクロ−ｒｎａおよびその使用
EP3658157B1 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2011142744A1 (en) Compositions and methods for the treatment and prevention of cardiac ischemic injury
ES2906333T3 (es) Composiciones y procedimientos para el diagnóstico y tratamiento de trastornos del sistema linfático
He et al. Functions and application of circRNAs in vascular aging and aging-related vascular diseases
JP5737721B2 (ja) Ｈｔｒａ１変異と家族性虚血性脳小血管病との関連
US20150031742A1 (en) Treatment of uterine leiomyomata
US9834820B2 (en) Methods for the treatment and diagnosis of bone mineral density related diseases
US20250186546A1 (en) Compositions and Methods to Prevent, Inhibit or Treat Autoimmune and Vascular Disease
Gong et al. Macrophage-secreted U2AF1 orchestrates coronary artery angiogenesis to facilitate myocardial infarction repair through the regulation of Yap1 Variable splicing
Li et al. Recombinant egfl7 mitigated pressure overload-induced cardiac remodeling by blocking pi3k γ/akt/nfκb signaling in macrophages
EP4487854A1 (en) Pharmaceutical composition for treatment or prevention of fibrotic disease
WO2023183822A1 (en) Hematopoietic loss of y chromosome leads to cardiac fibrosis and dysfunction and is associated with death due to heart failure
US12605398B2 (en) CRISPR-based compositions for treating vascular disorders
JP2011502162A (ja) 変形性関節症遺伝子治療
Zhang et al. Interleukin enhancer binding factor 3 exacerbates cardiac inflammation and injury following myocardial infarction by inhibiting Lys48-linked ubiquitination on HNRNPA2B1 in macrophages
JP2017505771A (ja) 血管リモデリング
Brahami et al. Facial cutaneo-mucosal venous malformations can develop independently of mutation of TEK gene but may be associated with excessive expression of Src and p-Src
Pace et al. Precision Medicine for Sickle Cell Disease: Discovery of Genetic Targets for Drug Development
US20190185852A1 (en) Therapeutically modulating apob and apoai
US20170022503A1 (en) Methods of modulating wars2
US20220151921A1 (en) Monocyte-selective drug delivery system using single-walled carbon nanotubes to induce efferocytosis